The contract is awarded for products that bring improvement to the healthcare industry.Coloplast, a global medical device company and market ...

Coloplast announced it will acquire wound care product company Kerecis for $1.3 billion. The acquisition will give Coloplast an opportunity to “strategically strengthen [its] presence in the advanced ...

Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, ...

The new intermittent catheter Luja™ addresses important risk factors for urinary tract infections, a significant burden for people using intermittent catheters as well as healthcare systems as a whole ...

Coloplast is a leading global supplier of intimate healthcare products with a strong product portfolio and high market share. The company has a stable business model and benefits from demographic ...

The female intermittent catheter enables complete bladder emptying in one free flow1, aiming to reduce the risk of urinary tract infections2. Following the successful launch of Luja with Micro-hole ...

Coloplast A/S is about to launch a new single-use male intermittent catheter featuring new technology designed to reduce the risk of urinary tract infections (UTI). “The Luja device, with its ...

Though foreign-exchange headwinds have nagged at Coloplast COLO B, underlying demand remains robust and revenue growth remains on track to meet our full-year projections. We’re holding steady on our ...

Coloplast A/S is acquiring Kerecis hf, a closely held Icelandic maker of fish-skin dressings to treat human wounds, for an enterprise value of up to $1.3 billion. Coloplast is making a $1.2 billion ...

Narrow-moat Coloplast COLO B kicked off its new fiscal year in strong fashion, despite diminishing ripple effects from the pandemic, and we’re leaving our fair value estimate unchanged. Quarterly ...

Coloplast is growing with extreme consistency and first quarter results were in-line again with previous top line growth. The company is not only growing with high consistency but also has extremely ...

According to the Market Abuse Regulation article 19 Coloplast is obliged to report on the transactions of executives and their related parties in Coloplast shares and related securities. The below ...